Bristol-Myers Squibb (BMY) says it's stopped development of an experimental hepatitis C...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) says it's stopped development of an experimental hepatitis C treatment connected to the hospitalization of nine patients and the death of one. The drug, known as BMS-986094, had been used in a mid-stage clinical study, which BMY recently suspended. The cause of the adverse events, while not "definitively established," involved heart and kidney toxicity, the drug maker said.